Strategy At Novartis: Culture Change As The 'How' Behind The 'What'
Executive Summary
If strategic planning is a necessary hedge against the drawn-out, asset-draining product cycles of today’s big pharma enterprise, then what is the secret of doing it well? In Vivo looks for answers in a conversation with Novartis strategy lead Stephen Moran.
You may also be interested in...
Novartis Enters ‘Transformational’ Cloud Computing Pact With Amazon
Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.
Syntekabio Aiming To Be Pharma Companion In AI-Driven Drug Development
Syntekabio is at the forefront of artificial intelligence-driven new drug development in South Korea. Its CEO Tyson Kim talks to Scrip how the genome big data and AI platform company is helping the pharma industry to develop new drugs more efficiently and rapidly.
Viz.ai: Precision Targeting Of Every Patient’s Medical “Moment Of Truth”
Viz.ai is making artificial intelligence real and ready with an algorithm-based detection and diagnostics platform that is beating the clinical clock in fighting stroke. The start-up is now focused on positioning its joined-up AI software as standard-setter for broader patient engagement with big pharma on everything from participation in clinical trials to launching the next generation of high-touch specialty medicines.